keyword
MENU ▼
Read by QxMD icon Read
search

neda AND "multiple sclerosis"

keyword
https://read.qxmd.com/read/30849681/efficacy-and-safety-of-alemtuzumab-in-korean-multiple-sclerosis-patients
#1
Hyunjin Kim, Eun-Jae Lee, Sung Keun Kim, Kwang-Kuk Kim, Young-Min Lim
BACKGROUND: Efficacy and safety profiles of alemtuzumab for relapsing-remitting multiple sclerosis (RRMS) mainly come from Western countries and have not been reported in Asian populations. The aim of this study was to report the efficacy and safety of alemtuzumab for RRMS patients in a Korean population. METHODS: We retrospectively reviewed RRMS patients treated with alemtuzumab. Study outcomes included annualized relapse rate (ARR), expanded disability status scale (EDSS) score, 6-month confirmed disability worsening (CDW), confirmed disability improvement (CDI), MRI lesion activity (new/enlarging T2 hyperintense and gadolinium-enhancing T1 lesions), no evidence of disease activity (NEDA), and adverse events...
March 2, 2019: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/30820880/assessing-the-metabolomic-profile-of-multiple-sclerosis-patients-treated-with-interferon-beta-1a-by-1-h-nmr-spectroscopy
#2
Lorena Lorefice, Federica Murgia, Giuseppe Fenu, Jessica Frau, Giancarlo Coghe, Maria Rita Murru, Stefania Tranquilli, Andrea Visconti, Maria Giovanna Marrosu, Luigi Atzori, Eleonora Cocco
Metabolomic research has emerged as a promising approach to identify potential biomarkers in multiple sclerosis (MS). The aim of the present study was to determine the effect of interferon beta (IFN ß) on the metabolome of MS patients to explore possible biomarkers of disease activity and therapeutic response. Twenty-one MS patients starting IFN ß therapy (Rebif® 44 μg; s.c. 3 times per week) were enrolled. Blood samples were obtained at baseline and after 6, 12, and 24 months of IFN ß treatment and were analyzed by high-resolution nuclear magnetic resonance spectroscopy...
February 28, 2019: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/30792716/ethyl-pyruvate-induces-tolerogenic-dendritic-cells
#3
Neda Djedovic, María José Mansilla, Bojan Jevtić, Juan Navarro-Barriuso, Tamara Saksida, Eva M Martínez-Cáceres, Ðorđe Miljković
Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine model. Here, we expanded our study to its tolerogenic effects on DC...
2019: Frontiers in Immunology
https://read.qxmd.com/read/30719080/comparing-longitudinal-brain-atrophy-measurement-techniques-in-a-real-world-multiple-sclerosis-clinical-practice-cohort-towards-clinical-integration
#4
H N Beadnall, C Wang, W Van Hecke, A Ribbens, T Billiet, M H Barnett
Background: Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of longitudinal WBA in MS patients. Methods: Magnetic resonance imaging (MRI) scan pairs [1.05 (±0.15) year separation] from 102 MS patients were acquired on the same 3T scanner...
2019: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/30696913/oral-neonatal-antibiotic-treatment-perturbs-gut-microbiota-and-aggravates-central-nervous-system-autoimmunity-in-dark-agouti-rats
#5
Suzana Stanisavljević, Aleksa Čepić, Svetlana Bojić, Katarina Veljović, Sanja Mihajlović, Neda Đedović, Bojan Jevtić, Miljana Momčilović, Milica Lazarević, Marija Mostarica Stojković, Đorđe Miljković, Nataša Golić
Gut microbiota dysbiosis has been considered the essential element in the pathogenesis of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). Antibiotics were administered orally to Dark Agouti (DA) rats early in their life with the aim of perturbing gut microbiota and investigating the effects of such intervention on the course of EAE. As a result, the diversity of the gut microbiota was reduced under the influence of antibiotics. Mainly, Firmicutes and Actinobacteria were replaced by Proteobacteria and Bacteroidetes, while decreased proportions of Clostridia and Bacilli classes were accompanied by an increase in Gamma-Proteobacteria in antibiotic-treated animals...
January 29, 2019: Scientific Reports
https://read.qxmd.com/read/30661133/treatment-with-alemtuzumab-or-rituximab-after-fingolimod-withdrawal-in-relapsing-remitting-multiple-sclerosis-is-effective-and-safe
#6
Carmen Alcalá, F Gascón, Francisco Pérez-Miralles, J A Domínguez, S Gil-Perotín, B Casanova
BACKGROUND: It has been described that treating relapsing-remitting multiple sclerosis (RRMS) patients with alemtuzumab following fingolimod could be less effective due to the different dynamics of lymphocyte repopulation. Effectiveness and safety of alemtuzumab compared to rituximab after fingolimod withdrawal were analyzed. PATIENTS AND METHODS: A follow-up of a cohort of RRMS patients treated with alemtuzumab or rituximab after fingolimod withdrawal was accomplished...
January 19, 2019: Journal of Neurology
https://read.qxmd.com/read/30635477/rituximab-vs-placebo-induction-prior-to-glatiramer-acetate-monotherapy-in-multiple-sclerosis
#7
Justin M Honce, Kavita V Nair, Stefan Sillau, Brooke Valdez, Augusto Miravalle, Enrique Alvarez, Teri Schreiner, John R Corboy, Timothy L Vollmer
OBJECTIVE: To examine whether rituximab induction followed by glatiramer acetate (GA) monotherapy is more effective than GA alone for the treatment of relapsing multiple sclerosis with active disease. METHODS: This was a single-center, double-blind, placebo-controlled study. Fifty-five participants were randomly assigned (1:1 ratio) to either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy initiated in all participants. Participants were followed up to 3 years...
February 12, 2019: Neurology
https://read.qxmd.com/read/30620337/loss-of-the-sphingolipid-desaturase-degs1-causes-hypomyelinating-leukodystrophy
#8
Devesh C Pant, Imen Dorboz, Agatha Schlüter, Stéphane Fourcade, Nathalie Launay, Javier Joya, Sergio Aguilera-Albesa, Maria Eugenia Yoldi, Carlos Casasnovas, Mary J Willis, Montserrat Ruiz, Dorothée Ville, Gaetan Lesca, Karine Siquier-Pernet, Isabelle Desguerre, Huifang Yan, Jinming Wang, Margit Burmeister, Lauren Brady, Mark Tarnopolsky, Carles Cornet, Davide Rubbini, Javier Terriente, Kiely N James, Damir Musaev, Maha S Zaki, Marc C Patterson, Brendan C Lanpher, Eric W Klee, Filippo Pinto E Vairo, Elizabeth Wohler, Nara Lygia de M Sobreira, Julie S Cohen, Reza Maroofian, Hamid Galehdari, Neda Mazaheri, Gholamreza Shariati, Laurence Colleaux, Diana Rodriguez, Joseph G Gleeson, Cristina Pujades, Ali Fatemi, Odile Boespflug-Tanguy, Aurora Pujol
Sphingolipid imbalance is the culprit in a variety of neurological diseases, some affecting the myelin sheath. We have used whole exome sequencing in patients with undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid desaturase DEGS1 as the causative gene in nineteen patients from thirteen unrelated families. Shared features among the cases include severe motor arrest, early nystagmus, dystonia, spasticity and profound failure to thrive. MRI showed hypomyelination, thinning of corpus callosum and progressive thalami and cerebellar atrophy, suggesting a critical role of DEGS1 in myelin development and maintenance...
January 8, 2019: Journal of Clinical Investigation
https://read.qxmd.com/read/30569270/correction-to-oral-disease-modifying-treatments-for-relapsing-multiple-sclerosis-a-likelihood-to-achieve-no-evidence-of-disease-activity-or-harm-analysis
#9
Dimitrios Papadopoulos, Dimos-Dimitrios D Mitsikostas
NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions.
December 20, 2018: CNS Drugs
https://read.qxmd.com/read/30564615/neurofilament-light-chain-serum-levels-correlate-with-10-year-mri-outcomes-in-multiple-sclerosis
#10
Tanuja Chitnis, Cindy Gonzalez, Brian C Healy, Shrishti Saxena, Mattia Rosso, Christian Barro, Zuzanna Michalak, Anu Paul, Pia Kivisakk, Camilo Diaz-Cruz, Neda Sattarnezhad, Isabelle V Pierre, Bonnie I Glanz, Davorka Tomic, Harald Kropshofer, Dieter Häring, David Leppert, Ludwig Kappos, Rohit Bakshi, Howard L Weiner, Jens Kuhle
Objective: To assess the value of annual serum neurofilament light (NfL) measures in predicting 10-year clinical and MRI outcomes in multiple sclerosis (MS). Methods: We identified patients in our center's Comprehensive Longitudinal Investigations in MS at Brigham and Women's Hospital (CLIMB) study enrolled within 5 years of disease onset, and with annual blood samples up to 10 years ( n = 122). Serum NfL was measured using a single molecule array (SIMOA) assay...
December 2018: Annals of Clinical and Translational Neurology
https://read.qxmd.com/read/30563943/food-allergies-are-associated-with-increased-disease-activity-in-multiple-sclerosis
#11
Rami Fakih, Camilo Diaz-Cruz, Alicia S Chua, Cindy Gonzalez, Brian C Healy, Neda Sattarnezhad, Bonnie I Glanz, Howard L Weiner, Tanuja Chitnis
OBJECTIVE: The association between allergy and multiple sclerosis (MS) is still unclear. In our study, we assessed the association between a self-reported history of allergic conditions with MS clinical and MRI disease activity. METHODS: A subset of 1349 patients enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB) study completed a self-administered questionnaire on environmental, food and drug allergies...
December 18, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/30539030/safety-and-efficacy-of-rituximab-in-multiple-sclerosis-a-retrospective-observational-study
#12
Bassem I Yamout, Nabil K El-Ayoubi, Johny Nicolas, Yehya El Kouzi, Samia J Khoury, Maya M Zeineddine
Objective: To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical practice setting. Methods: Clinical data for all adult patients with multiple sclerosis (MS) treated with off-label rituximab at a single MS center in Lebanon between March 2008 and April 2017 were retrospectively collected from medical charts. The main efficacy outcomes assessed were annualized relapse rate (ARR) and proportion of patients free from relapses, disability progression, or magnetic resonance imaging (MRI) activity...
2018: Journal of Immunology Research
https://read.qxmd.com/read/30513578/multiple-sclerosis-a-global-concern-with-multiple-challenges-in-an-era-of-advanced-therapeutic-complex-molecules-and-biological-medicines
#13
Victor M Rivera
Multiple sclerosis (MS) has become a common neurological disorder involving populations previously considered to be infrequently affected. Genetic dissemination from high- to low-risk groups is a determining influence interacting with environmental and epigenetic factors, mostly unidentified. Disease modifying therapies (DMT) are effective in treating relapsing MS in variable degrees; one agent is approved for primary progressive disease, and several are in development. In the era of high-efficacy medications, complex molecules, and monoclonal antibodies (MAB), including anti-VLA4 (natalizumab), anti-CD52 (alemtuzumab), and anti-CD20 (ocrelizumab), obtaining NEDA (no evidence of disease activity) becomes an elusive accomplishment in areas of the world where access to MS therapies and care are generally limited...
November 30, 2018: Biomedicines
https://read.qxmd.com/read/30488803/molecular-mechanisms-of-curcumin-in-neuroinflammatory-disorders-a-mini-review-of-current-evidences
#14
Mahsa Hatami, Mina Abdolahi, Neda Soveyd, Mahmoud Djalali, Mansoureh Togha, Niyaz Mohammadzadeh Honarvar
OBJECTIVE: Neuroinflammatory disease is a general term used to denote the progressive loss of neuronal function or structure. Many neuroinflammatory diseases, including Alzheimer's, Parkinson's, and multiple sclerosis (MS), occur due to neuroinflammation. Neuroinflammation increases nuclear factor-κB (NF-κB) levels, cyclooxygenase-2 enzymes and inducible nitric oxide synthase, resulting in the release of inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α)...
November 28, 2018: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/30443887/immune-reconstitution-therapy-irt-in-multiple-sclerosis-the-rationale
#15
REVIEW
Dimitrios Karussis, Panayiota Petrou
Immunotherapy of multiple sclerosis (MS) and other neuroimmune diseases is rapidly evolving. For the past 25 years, there has been an accelerating inclusion of new immunomodulating drugs. Based on their molecular construction and their basic mechanism of action, immunotherapeutic agents belong to the following categories: (1) cytotoxic drugs, (2) synthetic immunomodulators, (3) monoclonal antibodies, (4) vaccines (T cell vaccines, antigen vaccines), (5) oral tolerizing agents, (6) modalities that act as indirect immunosuppressants (plasmapheresis, intravenous immunoglobulins [IVIG]), and (7) cellular therapies...
November 16, 2018: Immunologic Research
https://read.qxmd.com/read/30401571/brain-volume-loss-and-no-evidence-of-disease-activity-over-3-years-in-multiple-sclerosis-patients-under-interferon-beta-1a-subcutaneous-treatment
#16
J I Rojas, F Sanchez, F Caro, J Miguez, L Patrucco, J Funes, E Cristiano
The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up. Relapsing remitting MS (RRMS) patients, with less than three years from disease onset, expanded disability status scale (EDSS) ≤3 and in which IFN beta 1-a 44 mcg was indicated, were included. Demographic, clinical and structural parameters from the magnetic resonance (MR) during the 3 years of follow up were analyzed and compared between patients with and without NEDA (defined as the absence of: (a) three-month confirmed disability progression defined as an increase in EDSS score of 1...
November 3, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://read.qxmd.com/read/30386435/neda-3-status-including-cortical-lesions-in-the-comparative-evaluation-of-natalizumab-versus-fingolimod-efficacy-in-multiple-sclerosis
#17
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini, Paolo Gallo
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the 'no evidence of disease activity' (NEDA) definition should now include CLs. The aim of this study was to evaluate the NEDA3 + CL status in natalizumab- or fingolimod-treated relapsing remitting MS (RMS) patients. Methods: Natalizumab- or fingolimod-treated RMS patients were enrolled in a 2-year longitudinal study based on clinical and magnetic resonance imaging (MRI) evaluations performed respectively biannually and annually...
2018: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/30384198/no-evidence-of-disease-activity-status-over-3-years-in-a-real-world-cohort-of-relapsing-remitting-ms-patients-in-germany
#18
Konstantin Huhn, Daniela Senger, Kathrin S Utz, Manuel Schmidt, Kilian Fröhlich, Anne Waschbisch, Frank Seifert, Arnd Dörfler, De-Hyung Lee, Ralf A Linker
BACKGROUND: Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolved with the approval of several new treatment concepts. Thus, treatment goals have become more ambitious aiming at "no evidence of disease activity" (NEDA). As NEDA-3, this concept comprises freedom of clinical disease progression and relapses as well as inflammatory MRI activity. So far, data on NEDA status mainly stem from post-hoc analyses of drug approval studies. Yet, less is known about the significance of NEDA in "real-world" clinical settings...
October 23, 2018: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/30259178/no-evidence-of-disease-activity-neda-3-and-disability-improvement-after-alemtuzumab-treatment-for-multiple-sclerosis-a-36-month-real-world-study
#19
Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio, Valeria Barcella, Assunta Bianco, Deborah Farina, Elisabetta Ferraro, Simona Pontecorvo, Franco Granella, Luigi M E Grimaldi, Alice Laroni, Giacomo Lus, Francesco Patti, Eugenio Pucci, Matteo Pasca, Paola Sarchielli
In this retrospective, multicenter, real-world study we collected clinical and magnetic resonance imaging (MRI) data of all patients (n = 40) with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab according to a "free-of-charge" protocol available before the drug marketing approval in Italy. Almost all (39/40) started alemtuzumab after discontinuing multiple disease-modifying treatments (DMTs) because of either lack of response or safety concerns. We considered the proportion of alemtuzumab-treated patients who had no evidence of disease activity (NEDA-3) and disability improvement over a 36-month follow-up period...
December 2018: Journal of Neurology
https://read.qxmd.com/read/30234431/silent-lesions-on-mri-imaging-shifting-goal-posts-for-treatment-decisions-in-multiple-sclerosis
#20
Myintzu Min, Tim Spelman, Alessandra Lugaresi, Cavit Boz, Daniele LA Spitaleri, Eugenio Pucci, Francois Grand'Maison, Franco Granella, Guillermo Izquierdo, Helmut Butzkueven, Jose Luis Sanchez-Menoyo, Michael Barnett, Marc Girard, Maria Trojano, Pierre Grammond, Pierre Duquette, Patrizia Sola, Raed Alroughani, Raymond Hupperts, Steve Vucic, Tomas Kalincik, Vincent Van Pesch, Jeannette Lechner-Scott
BACKGROUND: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. OBJECTIVE: To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. METHODS: Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions...
October 2018: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
158178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"